Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Venus Remedies is currently trading at Rs. 200.00, up by 26.50 points or 15.27% from its previous closing of Rs. 173.50 on the BSE.
The scrip opened at Rs. 174.00 and has touched a high and low of Rs. 203.70 and Rs. 173.35 respectively. So far 107177 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 275.95 on 28-Jul-2011 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 203.70 and Rs. 162.00 respectively. The current market cap of the company is Rs. 175.71 crore.
The promoters holding in the company stood at 30.42% while Institutions and Non-Institutions held 15.83% and 53.75% respectively.
Venus Remedies has achieved another landmark by fetching its first patent grant from Japan patent office (JPO) which is among the most stringent pharma market in the world. This patent has been granted for its novel research product Vancoplus which has been designed to curb the growing bacterial resistance specially caused by the notorious MRSA strain which is usually termed as one of the Superbugs.
During the past four decades, Methicillin- Resistant Staphylococcus Aureus (MRSA) has evolved from a controllable nuisance into a serious public health concern. Vancoplus is the only known remedy to control MRSA, VRSA (Vancomycin Resistant Staphylococcus Aureus) and multi drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditic.
The market size of MRSA in the world accounts for about $900 million, presently, it is growing with CAGR of 4.8 percent, which is estimated to reach to $1.2 billion by 2017.
The company intends to launch this research product in early 2015. Currently, Vancoplus is available in emerging markets and is under registration ion many countries. Venus intends to out-license Vanocoplus across patent protected regions to major pharmaceutical players.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
